Skip to main content
. 2021 May 6;13(9):2234. doi: 10.3390/cancers13092234

Figure 1.

Figure 1

Frequency of tumor infiltrating CD8+CD28+ T cells, CD8+CD28− T cells and CD8+CD28−CD127−CD39+ Treg from HNSCC patients. (A–C): Comparative analysis of the frequencies of CD8+CD28+ T cells (Panel A), CD8+CD28− T cells (Panel B) and CD8+CD28−CD127−CD39+ Treg (Panel C) between Group 1 and Group 2 patients. (D–F): Survival of HNSCC patients divided into two groups based on the median (calculated in the overall population) of frequency of either CD8+CD28+ T lymphocytes (> or <47.5%) (Panel D), CD8+CD28− T lymphocytes (> or <52.5%) (Panel E) or CD8+CD28−CD127−CD39+ Treg (> or <13.5%) (Panel F).